106 - Still the One? Debating Vancomycin as First-Line MRSA Agent in New Era of AUC/MIC Dosing and Monitoring

Friday, October 21, 2022

8:00 AM – 9:00 AM US ET

Location: 147 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Christopher Bland, PharmD, FCCP, FIDSA, BCPS

Clinical Professor
Pharmacy
University of Georgia College of Pharmacy
Savannah, Georgia, United States

Disclosure(s): bioMerieux Inc.: Honoraria (Ongoing); Merck: Advisor/Consultant (Ongoing), Honoraria (Ongoing)
Stephanie Shealy May, PharmD

Infectious Diseases and Antimicrobial Stewardship Telehealth Pharmacist
Intermountain Healthcare
Salt Lake City, UT, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Marc Scheetz, PharmD, MSc

Professor and Director of Pharmacometrics Center of Excellence
Pharmacy and Pharmacology
Midwestern University
Downers Grove, Illinois, United States

Disclosure(s): Abbvie: Advisor/Consultant (); Allecra: Grant/Research Support (); Merck: Advisor/Consultant (); Nevakar: Advisor/Consultant (), Grant/Research Support (); Premier Healthcare Solutions: Honoraria (); Spero: Advisor/Consultant (); SuperTrans Medical: Advisor/Consultant (), Grant/Research Support (); Takeda: Advisor/Consultant (); Third Pole Therapeutics: Advisor/Consultant ()
Jamie L. Wagner, PharmD, BCPS, BCIDP

Clinical Associate Professor
University of Mississippi School of Pharmacy
Jackson, MS, United States

Disclosure(s): Shionogi & Co., Ltd.: Advisor/Consultant (Ongoing)

Disclosure(s):

Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS: bioMerieux Inc.: Honoraria (Ongoing); Merck: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Stephanie Shealy May, PharmD: No financial relationships to disclose

Marc H. Scheetz, PharmD, MSc: Abbvie: Advisor/Consultant (); Allecra: Grant/Research Support (); Merck: Advisor/Consultant (); Nevakar: Advisor/Consultant (), Grant/Research Support (); Premier Healthcare Solutions: Honoraria (); Spero: Advisor/Consultant (); SuperTrans Medical: Advisor/Consultant (), Grant/Research Support (); Takeda: Advisor/Consultant (); Third Pole Therapeutics: Advisor/Consultant ()

Jamie L. Wagner, PharmD, BCPS, BCIDP: Shionogi & Co., Ltd.: Advisor/Consultant (Ongoing)

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe rationale for vancomycin with AUC dosing/monitoring as first-line MRSA agent;
detail rationale for non-vancomycin therapies as the new first-line agents for MRSA;
determine, based on the evidence presented, the ultimate role of each agent presented for the treatment of MRSA in 2022

Presentations:

8:00 AM – 8:30 AM US ET

Pro: Vancomycin Is Still the One
Speaker: Marc H. Scheetz, PharmD, MSc – Midwestern University
8:30 AM – 9:00 AM US ET

Con: It Is Time for Alternative MRSA Agents
Speaker: Jamie L. Wagner, PharmD, BCPS, BCIDP – University of Mississippi School of Pharmacy